Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064863 | 0.93 | KDM4E (0.39) | KDM4ETAS1R3TAS1R1NT5E | |
| SCHEMBL7063493 | 0.80 | P2RY12 (0.34) | — | |
| SCHEMBL7063505 | 0.80 | HINT1 (0.38) | TAS1R3TAS1R1NT5E | |
| SCHEMBL7901421 | 0.78 | TK1 (0.32) | — | |
| SCHEMBL10276803 | 0.76 | TYMP (0.44) | KDM4ETAS1R3TAS1R1NT5E | |
| SCHEMBL6397988 | 0.74 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL7065334 | 0.73 | P2RY12 (0.35) | — | |
| SCHEMBL5576828 | 0.72 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL7063477 | 0.72 | ADORA1 (0.46) | NT5E | |
| SCHEMBL1738254 | 0.71 | TK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624294-B2 | Dissolving nucleoside in solvent to form a solution; cooling; treating with base; warming; reacting with ester to effect alkylation of 2' position of a 2',3'-dihydroxy sugar moiety of a nucleoside | ISIS PHARMACEUTICALS, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | IONIS PHARMACEUTICALS, INC. | 2003-04-24 | — | — | US | disclosed |
| US-6403779-B1 | DISSOLVING NUCLEOSIDE IN APROTIC SOLVENT, COOLING, TREATING WITH BASE, WARMING MIXTURE, COOLING, REACTING WITH REACTIVE ESTER TO EFFECT ALKYLATION | ISIS PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078415-A1 | Regioselective synthesis of 2'-O-modified nucleosides | NSUN2, NT5C3B, RNGTT | KDM4E 2034/4885TAS1R3 4469/4885TAS1R1 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.